Edition:
United Kingdom

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

4.22USD
23 Feb 2018
Change (% chg)

$-0.05 (-1.17%)
Prev Close
$4.27
Open
$4.31
Day's High
$4.32
Day's Low
$4.15
Volume
512,211
Avg. Vol
243,137
52-wk High
$5.43
52-wk Low
$1.93

Chart for

About

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $329.60
Shares Outstanding(Mil.): 109.14
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.19 16.60
EPS (TTM): -- -- --
ROI: -- 13.90 10.66
ROE: -- 16.72 14.30

BRIEF-Cerus Announces Pricing Of Public Offering Of Common Stock

* CERUS CORP - ‍PRICING OF PUBLIC OFFERING OF ITS COMMON STOCK FOR PROCEEDS OF $50.0 MILLION, BEFORE DEDUCTING ESTIMATED OFFERING EXPENSES PAYABLE BY CERUS​ Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Cerus Announces Public Offering Of Common Stock

* CERUS CORP - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints

* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS

23 Jan 2018

BRIEF-Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million

* CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION

08 Jan 2018

BRIEF-Cerus receives IDE approval to initiate phase iii recepi study

* Cerus Corporation receives IDE approval to initiate phase iii recepi study Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Cerus Corp reports Q3 loss per share $0.12

* Q3 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S

02 Nov 2017

BRIEF-Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio

* Cerus and Kedrion Biopharma enter distribution agreement for the full INTERCEPT blood system portfolio in Italy

31 Oct 2017

BRIEF-Cerus announces agreement with transfusion Center of the Community of Madrid

* Cerus announces agreement with transfusion Center of the Community of Madrid

30 Oct 2017

BRIEF-CERUS ANNOUNCES NATIONAL GERMAN REIMBURSEMENT FOR PATHOGEN INACTIVATED PLATELETS

* CERUS SAYS ‍INSTITUTE FOR HOSPITAL REMUNERATION SYSTEM IN GERMANY WILL INCLUDE PATHOGEN-INACTIVATED PLATELETS FOR NATIONAL REIMBURSEMENT STARTING JAN 1, 2018​ Source text for Eikon: Further company coverage:

23 Oct 2017

Competitors

  Price Chg
Terumo Corp (4543.T) ¥5,470 +10.00
Grifols SA (GRLS.MC) €23.55 +0.11
Grifols SA (GRLSbn.MC) €18.40 +0.06

Earnings vs. Estimates